HLS Therapeutics Inc. HLS.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · hlstherapeutics.com
HLS Therapeutics Inc. is a Canadian specialty pharmaceutical company focused on the acquisition and commercialization of branded pharmaceuticals in the central nervous system and cardiovascular markets. Key products include CLOZARIL (clozapine) for the treatment of psychiatric disorders and VASCEPA (icosapent ethyl) for cardiovascular disease management in Canada and internationally.
Key ratios
FreeCashFlowOnSale TTM 0.3
FreeCashFlowOnSale 2025 0.3
FreeCashFlowOnSale 2024 0.14
FreeCashFlowOnSale 2023 0.25
NetIncomeMargin TTM -0.22
NetIncomeMargin 2025 -0.22
NetIncomeMargin 2024 -0.35
NetIncomeMargin 2023 -0.44
ReturnOnAssets TTM -0.02
ReturnOnAssets 2025 -0.02
ReturnOnAssets 2024 -0.03
ReturnOnAssets 2023 -0.03
ReturnOnEquity TTM -0.19
ReturnOnEquity 2025 -0.19
ReturnOnEquity 2024 -0.23
ReturnOnEquity 2023 -0.25
Recent news
HLS Therapeutics to Host Q2 2026 Financial Results Conference Call
2026-07-29 · CNW
HLS Therapeutics Reports Annual Meeting Results
2026-06-26 · Investing News Network
HLS Therapeutics Announces Normal Course Issuer Bid
2026-06-23 · Yahoo Finance / Newswire
HLS Therapeutics Announces Q1 2026 Financial Results
2026-05-15 · Newswire.ca